WMT - GSK's Competitive Edge Surpasses Pfizer in Respiratory Syncytial Virus Vaccine Sales | Benzinga
GSK (NYSE: GSK) has reportedly taken an early lead in the race for respiratory syncytial virus (RSV) vaccine dominance, surpassing Pfizer Inc (NYSE: PFE), which previously dominated the COVID-19 vaccine market.
GSK's RSV vaccine has gained significant traction in the U.S., with IQVIA data revealing that it accounts for nearly two-thirds of RSV shots administered since early September.
This early success can be attributed to GSK's strategic ...